Medical Isotopes and Alternatives for Diagnostic Imaging

The Canadian Agency for Drugs and Technologies in Health (CADTH) is undertaking a multifaceted project to support greater efficiency and effectiveness in the health system management of the medical isotope technetium-99m (^99mTc).

In light of recent global supply disruption of ^99mTc, CADTH will be developing guidance on how to prioritize the use of this medical isotope. The evaluation will also assess how ^99mTc compares with other medical imaging options, such as magnetic resonance imaging (MRI) or other medical isotopes.  

The goal of the project is to provide Canadian health care decision-makers with evidence-based guidance on policies, protocols, and standards related to ^99mTc. This will help support optimal access to appropriate medical imaging for Canadians.

• Find out more in the Project Backgrounder.
• Learn about the Medical Isotopes and Imaging Modalities Advisory Committee (MIIMAC), comprising experts from across Canada, who will help CADTH provide guidance on optimizing the use of medical isotopes.